What question did this study set out to answer?

To evaluate the efficacy of tenecteplase compared to best medical treatment in patients with acute ischemic stroke treated between 4.5 and 24 hours post-symptom onset.

June 13, 2026Open Access

Tenecteplase With or Without Mechanical Thrombectomy in Acute Ischemic Stroke at 4.5 to 24 h: An Updated Meta-Analysis of Randomized Controlled Trials

Key Points

To evaluate the efficacy of tenecteplase compared to best medical treatment in patients with acute ischemic stroke treated between 4.5 and 24 hours post-symptom onset.
Systematic search of RCTs in accordance with PRISMA guidelines comparing TNK with BMT in adult patients between 4.5 and 24 h.
Included seven RCTs involving 1754 patients with primary endpoint of good functional outcome at 90 days (mRS 0–2).
Meta-analytic pooling of ORs and HRs used for analyzing outcomes.
TNK-treated patients had higher good functional outcomes at 90 days (HR: 1.15; 95% CI: 1.03–1.27).
Rates of excellent functional outcome were significantly higher in the TNK group (HR: 1.29; 95% CI: 1.08–1.55).
Higher reperfusion rates were observed in TNK compared with BMT, reflecting better preservation of ischemic brain tissue.

Abstract

Background and Purpose: Tenecteplase (TNK) within 4.5 h from symptom onset is not inferior to alteplase in treating ischemic stroke. In recent years, some randomized controlled trials (RCTs) have investigated the efficacy of extending the therapeutic window up to 24 h. This updated meta-analysis aims to synthesize the results of these RCTs comparing TNK to the best medical treatment (BMT) with or without endovascular thrombectomy. Methods: In accordance with PRISMA guidelines, all RCTs comparing TNK with BMT in adult patients between 4.5 and 24 h were systematically searched. The primary endpoint was good functional outcome at 90 days (mRS 0–2). Secondary endpoints included excellent outcome (mRS 0–1), symptomatic intracerebral hemorrhage (sICH), 90-day mortality, complete reperfusion at 24 h. Odd and Hazard ratios (ORs; HRs) were pooled using meta-analytic methods. Results: A total of seven RCTs involving 1754 patients were included. The rates of the primary endpoint were higher in TNK-treated patients (HR: 1.15; 95% CI: 1.03–1.27), as were rates of excellent functional outcome (HR: 1.29; 95% CI: 1.08–1.55). In the subgroup receiving intravenous therapy (IVT) alone, the primary endpoint was significantly more frequent in the TNK group than in the BMT group (OR: 1.47; 95% CI: 1.17–1.84; p for heterogeneity < 0.0001). TNK treatment was also associated with higher reperfusion rates compared with BMT, reflecting a greater proportion of saved ischemic penumbra as assessed via perfusion imaging. Although symptomatic intracranial hemorrhage (sICH) occurred more frequently in TNK-treated patients, the difference did not reach statistical significance, and mortality rates were comparable between treatment groups. Conclusions: Tenecteplase administered between 4.5 and 24 h is associated with improved rates of both good and excellent functional outcomes compared with BMT, especially in patients treated with IVT alone. Additionally, TNK is linked to higher rates of reperfusion.

Tenecteplase With or Without Mechanical Thrombectomy in Acute Ischemic Stroke at 4.5 to 24 h: An Updated Meta-Analysis of Randomized Controlled Trials

Key Points

Abstract

Cite This Study

Also Consider

Also Consider